Since late 2020, SK Bioscience Inc. (a division of SK Group) has been producing a major proportion of the Vaxzevria vaccine (also known as COVID-19 Vaccine AstraZeneca), under license from the University of Oxford and AstraZeneca, for worldwide distribution through the COVAX facility under the WHO hospice. A recent agreement with Novavax expands its production for a second vaccine to 40 million doses in 2022, with a $450 million investment in domestic and overseas facilities.Dunleavy, Kevin (February 25, 2021). "With $900M IPO, SK Bioscience has big plans for manufacturing expansion—even beyond COVID-19 vaccines" FiercePharma. Retrieved April 24, 2021.
Since late 2020 SK Bioscience Inc (a division of SK Group) has been producing a major proportion of the Vaxzevria vaccine (also known as COVID-19 Vaccine AstraZeneca) under license from the University of Oxford and AstraZeneca for worldwide distribution through the COVAX facility under the WHO hospice A recent agreement with Novavax expands its production for a second vaccine to 40 million doses in 2022 with a $450 million investment in domestic and overseas facilitiesDunleavy Kevin (February 25 2021) "With $900M IPO SK Bioscience has big plans for manufacturing expansion—even beyond COVID-19 vaccines" FiercePharma Retrieved April 24 2021